NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 08 May 2017 (#16)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a ***selection*** *of pre-screened, currently open health funding opportunities for which* ***South African institutions are eligible to apply****. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

Please be advised that you ***must contact the Research Grants Management Office (RGMO) Pre-Awards*** *(Dr Christa de Vries cdevries@sun.ac.za)* ***to inform of your intent to apply.***

Timelines:

Confirm your intent to apply as soon as possible, but not later than 30 days before the submission date.

All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date.

The application will be submitted four (4) workdays before the application due date.

Important notices

1. **Your Application Will Be Withdrawn if You Don't Follow NIH's Appendix Policy**
2. **R03, R21 Opportunities on Primary Immunodeficiency Diseases Will Expire Early**
3. **Understanding Indirect Costs**
4. **What is the minimum level of effort required on a grant?**
5. **Is my application confidential?**
6. **Intensive Course in Fundamentals of Implementation Science in Global Health at the University of Washington, Seattle, WA. Citizens of non-OECD countries can request financial support in their applications. Application deadline: May 15, 2017**
7. **The Global Forum on Bioethics in Research (GFBR) meeting, The ethics of alternative clinical trial designs and methods in low- and middle- income country research, will be held in Bangkok, Thailand, November 28-29, 2017. Apply to participate (including full funding, travel and accommodation for LMIC applicants), and submit proposals on case studies, or on guidance and policy issues. Application deadline: May 30, 2017**
8. **New "FORMS-E" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2018 (NOT-OD-17-062)**
9. **Update Course in Clinical Tropical Medicine and Travelers' Health offered by the American Society of Tropical Medicine and Hygiene (ASTMH) in Toronto, Canada, June 14 - 15, 2017. Register by May 4, 2017 for reduced registration fees.**
10. **Annual Conference on the Science of Dissemination and Implementation in Health, co-sponsored by AcademyHealth and NIH, December 4 - 6, 2017, in Arlington, Virginia, U.S. A call for abstracts is expected to open in late May.**
11. **Request for Information on the Development of the FY 2019 Trans-NIH Plan for HIV-Related Research (NOT-OD-17-053) Office of AIDS Research**
12. **Notice of Informational Webinars for Investigators Applying for National Center for Complementary and Integrative Health (NCCIH) Clinical Trials (NOT-AT-17-009)**
13. **Notice of Information Regarding the "Announcement of Antimicrobial Resistance Rapid, Point-of-Need Diagnostic Test Challenge Competition" (NOT-OD-17-063)**

1. Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-MH-18-300) (RFA-MH-18-301) **Type:** ***R01*** ***R21***

Application Due Date: September 6, 2017. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

RFA-MH-18-300 uses the R01 grant mechanism while RFA-MH-18-301 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism.

Budget: NIMH intends to commit an estimate of $2,000,000 in FY 2018 to fund 3-5 awards in response to this FOA and the companion R21 FOA. Future year amounts will depend on annual appropriations. NINDS intends to commit approximately $1,000,000 in FY 2018 to fund 2-3 awards in response to this FOA and the companion R21 FOA. NIDA intends to commit approximately $1,500,000 in FY 2018 to fund 2-3 awards in response to this FOA and the companion R21 FOA. R01: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. R21: The combined budget for direct costs for the entire project period may not exceed $275,000. No more than $200,000 may be requested in any single year.

2. Modeling of Infectious Disease Agent Study Research Projects

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-267) **Type:** ***R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) supports innovative research that will develop and apply computational tools and methods for modeling interactions between infectious agents and their hosts, disease spread, prediction systems and response strategies. The models should be useful to researchers, policymakers, or public health workers who want to better understand and respond to infectious diseases. This research opportunity encourages applications from institutions/organizations that propose to provide the scientific and public health communities better resources, knowledge, and tools to improve their ability to prepare for, identify, detect, control, and prevent the spread of infectious diseases caused by naturally occurring or intentionally released pathogens, including those relevant to biodefense.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-269) **Type:** ***X01***

Application Due Date: Applications are accepted by continuous receipt. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI. Information about the current services offered can be accessed via: http://www.cidr.jhmi.edu.

Budget: Not Applicable; there is no budget associated with X01 Resource Access Awards.

4. Pilot / Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-271) (PAR-17-272) **Type:** ***R34*** ***R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) NIMH seeks applications for pilot effectiveness projects to evaluate the preliminary effectiveness of therapeutic and service delivery interventions for the post-acute management of mental health conditions that are matched to the stage of illness in terms of both their focus (e.g., consolidating and maintaining gains from initial treatment, managing residual symptoms/impairment, preventing relapse, promoting adherence and appropriate service use) and intensity/burden. In this pilot phase of effectiveness research, the trial should be designed to evaluate the feasibility, tolerability, acceptability, safety, and potential effectiveness of the approach; to address whether the intervention engages the target(s)/mechanisms(s) that is/are presumed to underlie the intervention effects; and to obtain preliminary data needed as a pre-requisite to a larger-scale effectiveness trial (e.g., comparative effectiveness study, practical trial) designed to definitely test the effectiveness of interventions to improve post-acute outcomes. This FOA supports pilot effectiveness research to evaluate the feasibility, tolerability, acceptability, safety and preliminary indications of effectiveness of post-acute phase intervention approaches and inform the design of definitive effectiveness trials. Support for fully-powered, definitive effectiveness studies focused on post-acute phase interventions is provided via the R01 in PAR-17-272.

Budget: R34:Direct costs are limited to $450,000 over the R34 project period, with no more than $225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this funding opportunity may not exceed three years. R01: Application budgets are not limited but need to reflect the actual needs of the proposed project. Scope of the proposed project should determine the project period. The maximum period is 5 years, however, most awards will be for 3-4 years.

5. Novel Cell Non-autonomous Mechanisms of Aging

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-AG-18-009) **Type:** ***R01***

Application Due Date: October 3, 2017. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) solicits applications on novel studies of cell non-autonomous mechanisms of aging. The goal of this FOA is to support applications that will lead to in-depth understanding of the mechanisms that produce cell non-autonomous aging signals: what they are, how they are generated from cell autonomous aging, how they are released from cells, how they are transported or communicated to other cells, and how they elicit aging upon reaching their target cells. Research supported by this FOA should lead to new insights and better understanding of the importance of cell non-autonomous mechanisms in aging at a tissue, system, or organismal level.

Budget: NIA intends to commit $3 million (total cost) in FY 2018 to fund 4-8 awards. Application budgets are limited to $250,000 in direct costs per year and need to reflect the actual needs of the proposed project. The scope of the project should determine the project period. The maximum project period is 5 years

6. Promoting NICHD Areas of Research for HIV/AIDS in Maternal and Child Health

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-17-262) **Type:** ***R01***

Application Due Date: Standard AIDS dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) stimulates HIV/AIDS research by addressing scientific areas of primary interest to NICHD, Maternal and Pediatric Infectious Disease Branch (MPIDB) and the Office of AIDS Research (OAR). This FOA will further explain our interests over the next three years.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

7. Innovation for HIV Vaccine Discovery

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-263) **Type:** ***R01***

Application Due Date: August 1, 2017; August 1, 2018; August 1, 2019. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) supports high risk, high impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high risk, high impact nature of this research, this FOA supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated "Go/No-Go" criteria by the end of Year 2.

Budget: Application budgets are limited to $350,000 per year in direct costs. Applicants may request up to an additional $150,000 per year in direct costs in any year when research in nonhuman primate or humanized mice models is proposed and justified. Project duration is no more than four years. Applicants should submit a 4 year project period, and are required to identify Go/No-Go decision criteria to be achieved for the Year 2 progress report to allow continued funding for years 3 and 4. Achievement of the stated goal(s) (Go) will enable continuation of the R01 for years 3 and 4, while failure to achieve the stated goal(s) (No-Go) will result in negotiation of a reduced budget for Year 3 and award close out.

8. Innovative Mental Health Services Research Not Involving Clinical Trials

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-264) **Type:** ***R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) encourages innovative research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial R01-level projects that address NIMH strategic priorities for mental health services research (see http://www.nimh.nih.gov/about/strategic-planning-reports/strategic-research-priorities/srp-objective-4/index.shtml). Proposed research should seek to:
1) Identify mutable factors that impact access, continuity, utilization, quality, value, and outcomes, including disparities in outcomes, or scalability of mental health services in the United States, which may serve as targets in future service delivery intervention development;
2) Develop and test new research tools, technologies, measures, or methods and statistical approaches to study these issues;
3) Integrate and analyze large data sets to understand factors affecting mental health services outcomes using sophisticated computational and predictive analytic approaches;
4) Wherever possible, leverage existing infrastructure and partnerships to accomplish these goals.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years; however, it is anticipated that most awards will be for 3 or 4 years.

9. *Eunice Kennedy Shriver* National Institute of Child Health and Human Development Exploratory/Developmental Research Grant

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-17-259) **Type: *R21***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The NICHD Exploratory/Developmental Grant program supports exploratory and developmental research projects that fall within the NICHD mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Budget: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. The maximum project period is two years.

10. PsychENCODE: Non-coding Functional Elements in the Human Brain and their Role in the Development of Psychiatric Disorders

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-257) **Type: *U01***

Application Due Date: July 6, 2017, June 6, 2018, June 6, 2019. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The objective of this FOA is to support research in the discovery and characterization of the full spectrum of human-specific non-coding functional genomic elements across brain regions, cell types, and developmental time periods to elucidate their role(s) in the molecular pathophysiology of mental illness. It is expected that projects under this FOA will apply unbiased genome-wide approaches, computational methods, and experimental assays to identify and characterize functional genomic elements in both healthy and diseased human brains to correlate findings with development of mental illnesses and outcomes relevant to brain function and dysfunction. Projects should work towards developing comprehensive maps of functional elements, including insulators, enhancers, promoters, silencers, transcription binding factors, non-coding RNAs (e.g., long non-coding RNAs [lncRNAs], microRNAs [miRNAs], piwi-interacting RNAs [piRNAs]), modifications to RNA, RNA spliceoforms, long-range chromatin interactions, DNA methylations, etc. This FOA should be used for applications that are not collaborative between sites. Applications requiring two or more collaborating sites to complete the proposed research should apply as a linked set of collaborative U01 applications to the companion collaborative U01 FOA (PAR-17-258). Projects awarded under this FOA and the companion FOA (PAR-17-258) will be governed by the PsychENCODE Consortium Executive Committee to facilitate and accelerate scientific progress through the coordination of research strategies, analytical methods, and data.

Budget: Application budgets are not limited, but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA may not exceed 5 years.

11. PsychENCODE: Non-coding Functional Elements in the Human Brain and their Role in the Development of Psychiatric Disorders (Collaborative U01)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-258) **Type: *Coll U01***

Application Due Date: July 6, 2017, June 6, 2018, June 6, 2019. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The objective of this FOA is to support research in the discovery and characterization of the full spectrum of human-specific non-coding functional genomic elements across brain regions, cell types, and developmental time periods to elucidate their role(s) in the molecular pathophysiology of mental illness. It is expected that projects under this FOA will apply unbiased genome-wide approaches, computational methods, and experimental assays to identify and characterize functional genomic elements in both healthy and diseased human brains to correlate findings with development of mental illnesses and outcomes relevant to brain function and dysfunction. Projects should work towards developing comprehensive maps of functional elements, including insulators, enhancers, promoters, silencers, transcription binding factors, non-coding RNAs (e.g., long non-coding RNAs [lncRNAs], microRNAs [miRNAs], piwi-interacting RNAs [piRNAs]), modifications to RNA, RNA spliceoforms, long-range chromatin interactions, DNA methylations, etc. This FOA should be used when two or more collaborating sites are essential to complete the proposed research. It is required that the Research Strategy be identical across linked collaborative U01 applications, with the exception of a short section describing the specific function of each application under "elements unique to that site." For a linked set of collaborative U01 applications, each application must have its own Program Director/Principal Investigator (PD/PI) and the program must provide a mechanism for cross-site coordination. Applications that stand alone and are not collaborative should be submitted under the companion U01 FOA (PAR-17-257). Projects awarded under this FOA and the companion FOA (PAR-17-257) will be governed by the PsychENCODE Consortium Executive Committee to facilitate and accelerate scientific progress through the coordination of research strategies, analytical methods, and data.

Budget: Application budgets are not limited, but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this FOA may not exceed 5 years.

12. Integrative Computational Biology for Analysis of NHLBI TOPMed Data

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (RFA-HL-18-020) **Type:** ***R01***

Application Due Date: July 6, 2017 and July 6, 2018. Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The purpose of this Funding Opportunity Announcement (FOA) is to support integrated analysis of whole genome, large scale "omic" data generated by the NHLBI's Trans-Omics for Precision Medicine (TOPMed) program and associated phenotype and clinical data using systems approaches. Ultimately, these studies will advance our understanding of the molecular underpinnings of heart, lung, blood, and sleep disease.

Budget: NHLBI intends to commit total costs of $3,000,000 in FY 2018, $6,000,000 in FY 2019, and $3,000,000 in FY 2020 to fund up to 12 awards. Application budgets may not exceed $324,000 in direct costs per year and must reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is two years.

13. From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-252) **Type:** ***Coll U01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and the orthogonal fields of the physical sciences (e.g., data/computational science, physics, engineering, mathematics). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, a successful team will be expected to have robust plan for sharing data and other resources. This FOA should be used when two or more collaborating sites are essential to complete the proposed research. It is required that the Research Strategy be identical across linked collaborative R01 applications, with the exception of a short section describing the specific function of each application under "elements unique to that site." For a linked set of collaborative R01 applications, each application must have its own Program Director/Principal Investigator (PD/PI) and the program must provide a mechanism for cross-site coordination. Applications that stand alone and are not collaborative should come in under the companion R01 FOA (PAR-17-253).

Budget: Application budgets may not exceed $500,000 direct cost annually for all applications combined in a collaborative set and are expected to reflect actual needs of the proposed project. The maximum project period is 5 years

14. From Genomic Association to Causation: A Convergent Neuroscience Approach for Integrating Levels of Analysis to Delineate Brain Function in Neuropsychiatry

Letter of Intent: 30 days prior to the application due date **Hyperlink:** **Type:** ***U01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) The primary objective of this FOA is to stimulate innovative Convergent Neuroscience (CN) approaches to establish causal and/or probabilistic linkages across contiguous levels of analysis (e.g., gene, molecule, cell, circuit, system, behavior) in an explanatory model of psychopathology. In particular, applicants should focus on how specific constituent biological processes at one level of analysis contribute to quantifiable properties at other levels, either directly or as emergent phenomena. Although not required, it is preferable that applications link at least three levels of analysis and include an emphasis on genetics. The projects under this FOA will develop novel methods, theories, and approaches through a CN team framework, bringing together highly synergistic inter/transdisciplinary teams from neuroscience and the orthogonal fields of the physical sciences (e.g., data/computational science, physics, engineering, mathematics). Successful teams will combine, expand upon, or develop conceptual frameworks and theoretical approaches, and build explanatory computational models that connect contiguous levels of analysis. Such frameworks, theories, and computational explanatory models should be validated through experimental approaches to elucidate biological underpinnings of complex behavioral (including cognitive and affective) outcomes in psychopathology. Additionally, a goal of this program is to advance research in CN by creating a shared community framework of resources which may be used by the broader research community to further research, as such, a successful team will be expected to have a robust plan for sharing data and other resources. This FOA should be used for applications that are not collaborative between sites. Applications requiring two or more collaborating sites to complete the proposed research should apply as a linked set of collaborative R01 applications to the companion collaborative R01 FOA (PAR-17-252).

Budget: Application budgets may not exceed $500,000 direct cost annually and are expected to reflect actual needs of the proposed project. The maximum project period is 5 years.

15. Collaborative R01s for Clinical Studies of Mental Illness Not Involving Clinical Trials

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-17-256) **Type:** ***Coll R01***

Application Due Date: Standard dates Apply by 5:00 PM local time of applicant organization.

This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the sites and are organized as such in order to increase sample size, accelerate recruitment, or increase sample diversity and representation. In studies with a large number of sites, it is expected that one site will be submitted as a coordinating R01 for data management and/or other centralized administration. For a linked set of collaborative R01s, each application has its own Program Director/Principal Investigator (PD/PI). The collaborative R01 program provides a mechanism for cross-R01 coordination, quality control, database management, statistical analysis, and reporting.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

Brief definitions of some NIH grant mechanisms: *comprehensive list of extramural grant and cooperative agreement activity codes*

D71 - International Research Training Planning Grant: To plan for the preparation of an application for a D43 international research training grant or for a U2R international research training cooperative agreement.

D43 - International Research Training Grants: To support research training programs for US and foreign professionals and students to strengthen global health research and international research collaboration.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <$275,000 (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for "new investigators"; not renewable; up to 2 years; budget generally <$50,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R34 - Clinical Trial Planning Grant Program: To provide support for the initial development of a clinical trial, including the establishment of the research team; the development of tools for data management and oversight of the research; the development of a trial design and other essential elements of the study, such as the protocol, recruitment strategies, and procedure manuals; and to collect feasibility data.

R35 - Outstanding Investigator Award: To provide long term support to an experienced investigator with an outstanding record of research productivity. This support is intended to encourage investigators to embark on long-term projects of unusual potential.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U19 - Research Program-Cooperative Agreements: supports a research program of multiple projects directed toward a specific major objective, basic theme or program goal, requiring a broadly based, multidisciplinary and often long-term approach. A cooperative agreement research program generally involves the organized efforts of large groups, members of which are conducting research projects designed to elucidate the various aspects of a specific objective.